tbuckley/cabot-search huggingface dataset:
Skin and bones. I
Authors: Seth J. Orlow, Kalman L. Watsky, Jean L. Bolognia
Journal: Journal of the American Academy of Dermatology (1991)

Skin disorders in which a radiograph may detect associated bony changes or abnormalities of calcification are discussed.They are grouped into eight categories: (1) inherited diseases (e.g., alkaptonuria, neurofibromatosis); (2) congenital disorders (e.g., Sturge-Weber and Proteus syndromes); (3) inflammatory conditions (e.g., dermatomyositis, sarcoidosis); ( 4) infections (e.g., dental sinus, syphilis); ( 5) neoplasias (e.g., histiocytosis, mastocytosis); ( 6) drug-and environment-induced (e.g., acroosteolysis, retinoid toxicity); (7) calcinosis cutis; and (8) osteoma cutis.Part I of our review discusses the first two categories.(J AM ACAD DERMATOL 1991;25:205-21.)There are numerous settings in which dermatology and radiology may complement each other to the benefit of the patient.Our aim is to present an overview of these settings.An emphasis of this review is on bony changes and abnormalities of calcification that may be readily detected by routine x-ray examination.We have divided the text on the basis of well-defined clinical disorders rather than radiographic findings.An effort was made to include a wide spectrum ofdiseases, but the list is by no means complete. INHERITED DISORDERS AlkaptonuriaThe ochronotic pigment that accumulates in patients with alkaptonuria and results in slate-blue or
ANTIBLASTIC IMMUNITY
Authors: A. R. Dochez, O. T. Avery
Journal: The Journal of Experimental Medicine (1916)

1. Antipneumococcus serum possesses the power of inhibiting for a certain period of time the multiplication of pneumococci. 2. It also has the capacity of inhibiting the proteolytic and glycolytc functions of pneumococci. 3. This power is acquired for the first time or appears in increased amounts in human serum at the time of crisis in lobar pneumonia. 4. The retardation of bacterial growth is thought to be dependent upon the inhibition of metabolic function due to the presence of anti-enzymotic substances in antipneumococcus serum. To this phenomenon we have applied the term antiblastic immunity.
Bioenergetics defect of CD14+ monocytes are associated with increased mortality in acute liver failure
Authors: Dhananjay Kumar, Ashini Hidam, Jitendra Kumar, Deepanshu Maheshwari, Mojahidul Islam, Nidhi Nautiyal, Viniyendra Pamecha, Rakhi Maiwall, Anupam Kumar, Shiv Kumar Sarin
Journal: Journal of Hepatology (2020)
Infections in Heroin Addicts
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nephrotoxicity associated with the use of cephaloridine
Authors: A. R. Hinman
Journal: JAMA (1967)

CEPHALORIDINE, a semisynthetic cephalosporin derivative which has recently been introduced for clinical evaluation,<sup>1-4</sup>has several advantages over cephalothin. It is a more potent agent in vitro, it is more soluble and causes less pain when injected, blood levels are higher, and less frequent injections are necessary due to slower renal clearance.<sup>5,6</sup>Possible disadvantages include less resistance to hydrolysis by staphylococcal beta-lactamase<sup>7,8</sup>and greater nephrotoxicity.<sup>4,5,9,10</sup>This report presents the case of a severely debilitated man infected with<i>Klebsiella</i>organisms, whose death was associated with uncontrolled infection and a nephrotoxic reaction to large doses of cephaloridine given intravenously. <h3>Report of a Case</h3> A 53-year-old white man was admitted to the hospital on Jan 6, 1965, complaining of weakness and shakiness of three weeks' duration and dyspnea, productive cough, chills, and fever for one week. Significant history included pulmonary tuberculosis 20 years previously and severe, chronic alcoholism. Physical examination
New initiative for global TB control
Authors: R. Voelker
Journal: JAMA (1995)

AN INTERNATIONAL group of experts has developed a set of recommendations for the global control of tuberculosis (TB), while lashing out at governments and pharmaceutical companies for ignoring the world's top infectious disease killer. Their strategy reiterates the importance of completed chemotherapy as a means to cure TB and prevent its spread. The broad-based recommendations note the promise of molecular techniques in new drug and vaccine development, as well as the roles that patient and physician behavior play in controlling the disease. But TB also is a highly political disease, experts stressed during a 2-day conference in Washington, DC, where they finalized the recommendations. London, England—based medical journal<i>The Lancet</i>sponsored the meeting and published the recommendations in its September 23 issue. The politics of TB have been evident in the United States for more than two decades, said Lee B. Reichman, MD, MPH, executive director of the New Jersey
THE SUPRARENALS IN HYPOGLYCEMIA
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE FORTY-NINTH ANNUAL REPORT ON MEDICAL EDUCATION
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Birth pangs: the stressful origins of lymphocytes
Authors: S. Pillai
Journal: Journal of Clinical Investigation (2005)

Inositol-requiring enzyme 1 (IRE1) is a transmembrane protein that signals from the ER and contributes to the generation of an active spliced form of the transcriptional regulator X-box–binding protein 1 (XBP1). XBP1 is required for the terminal differentiation of B lymphocytes into plasma cells, and IRE1 also participates in this differentiation event. A study in this issue of the JCI reveals, quite unexpectedly, that IRE1 is also required early in B lymphocyte development for the induction of the machinery that mediates Ig gene rearrangement.
Elderly (>=75) small-cell lung cancer (SCLC) chemotherapy: A phase I study of carboplatin (CBDCA) and etoposide (vp-16)
Authors: M. Fukuda, M. Oka, Y. Soejima, M. Fukuda, A. Kinoshita, H. Takatani, T. Kasai, M. Kuba, H. Soda, S. Kohno
Journal: Journal of Clinical Oncology (2004)

7217 Background: Elderly patients (>=75 year-old) have a great risk for chemotherapy, however, appropriate chemotherapy has improved survival and QOL in patients (pts) with SCLC. The combination with cisplatin and VP-16 is an active regimen for SCLC, and CBDCA is an analogue of cisplatin with less nonhematological toxicity. Based on these findings, we conducted a phase I study of CBDCA and VP-16 for elderly pts with SCLC. This study aimed to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT). Methods: Twenty-six pts fulfilling the eligibility criteria were enrolled; chemotherapy-naive, performance status (PS) 0–2, age>=75, and adequate hematological, hepatic and renal function. The pts received CBDCA with target AUC = 4–5 (Chatelut formula, Jaffe method) on day 1 and VP-16 80–120 mg/m2 i.v. on days 1, 2 and 3. Therapy was repeated 4 cycles in every 4 weeks and LD pts only received sequential thoracic radiotherapy. Results: Pts' characteristics: male/female = 21/5; PS 0/1/2 = 9/11/6; median age (range) = 77.5 (75–82); LD/ED = 16/10. The MTD dose of CBDCA/VP-16 were 5/80, 4/110 and 4/120. The DLT were thrombocytopenia, neutropenia, leukopenia and febrile neutropenia. Overall, grade 4 thrombocytopenia, neutropenia (>=4 days), leukopenia (>=4 days) and febrile neutropenia occurred 27%, 20%, 7% and 13% in MTD levels, respectively, and no in other levels. Twenty of 26 pts showed objective responses (2CR,18PR; RR = 77%). The median survival time was 14.4 (LD15.7, ED 8.3) months. Conclusions: The dose of CBDCA AUC = 4 and VP-16 100 mg/m2 was recommended in this therapy. No significant financial relationships to disclose.
Abstract 2184: SUMO-binding proteins as effectors and regulators of SUMO modification
Authors: Catherine M. Guzzo, Ijeoma Uzoma, Heng Zhu, Eric Cox, Seth Blackshaw, Michael J. Matunis
Journal: Cancer Research (2010)

Abstract SUMOs (Small Ubiquitin-related Modifiers) are reversibly conjugated to other proteins in the cell, thereby regulating a wide range of essential functions. Many of the functions regulated by SUMOylation are intimately tied to processes directly relevant to cancer, including maintenance of genome integrity and cell cycle regulation. Studies in the past several years have in fact linked SUMOylation to a variety of human cancers, including leukemia, prostrate, breast, and colon cancers. Thus, developing a fundamental understanding of the signals and factors that regulate SUMOylation, as well as how SUMOylation affects protein function, has the potential to lead to important new insights into cancer development, diagnosis, and treatment. We hypothesize that the three SUMO paralogs expressed in vertebrate cells (SUMO-1, SUMO-2 and SUMO-3), as well as their polymeric forms, represent unique signals recognized by unique proteins. Moreover, we propose that SUMOylation often promotes interactions between modified proteins and downstream factors containing SUMO-interacting motifs (SIMs). To test this hypothesis, we have initiated high throughput studies to identify novel SUMO-1, SUMO-2 and SUMO-2 polymeric chain binding proteins. Using microarray analysis, we identified ∼400 mostly nuclear proteins, many with preferential affinity for specific SUMO paralogs. Among these 400 putative SUMO-binding proteins was a family of zinc finger proteins that we have determined to possess a novel SIM. This family of proteins contains a stretch of unique tandem zinc fingers called MYM (myeloproliferative and mental retardation) domains. Although the exact functions of MYM-type zinc finger domains are not known, proteins containing these domains are linked to myeloproliferative syndromes, X-linked mental retardation, and transcriptional regulation. We have found that the MYM-type zinc finger domains are both necessary and sufficient for SUMO-binding. MYM-type zinc finger domains represent only the second known class of SUMO-binding motifs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2184.
Critique and Cavil
Authors: George X. Trimble
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anesthésie, Analgésie, Réanimation, Paris
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
News and Notices
Journal: British Journal of Dermatology (1988)

British Journal of DermatologyVolume 119, Issue 6 p. 809-809 News and Notices First published: December 1988 https://doi.org/10.1111/j.1365-2133.1988.tb03509.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume119, Issue6December 1988Pages 809-809 RelatedInformation
A controlled trial of HA-1A in a canine model of gram-negative septic shock
Authors: Z. M. Quezado
Journal: JAMA (1993)

<h3>Objectvie.</h3> —To investigate the therapeutic efficacy and microbiological and physiological effects of a human IgM monoclonal antibody (HA-1 A) directed against the lipid A component of endotoxin in a canine model of sepsis that simulates the cardiovascular abnormalities of human septic shock. <h3>Design.</h3> —Blinded, placebo-controlled 28-day trial. <h3>Interventions.</h3> —Purpose-bred beagles were implanted with an intraperitoneal clot infected with<i>Escherichia coli</i>O111:B4. At clot placement, animals received HA-1A (10 mg.kg<sup>-1</sup>), control human IgM antibody (10 mg.kg<sup>-1</sup>), or control human serum albumin intravenously. All animals were given antibiotic and fluid therapy. <h3>Measures.</h3> —Survival and microbiological and physiological events. <h3>Results.</h3> —Only two (15%) of 13 animals in the HA-1A group, compared with eight (57%) of 14 control animals (combined control human IgM antibody and control human serum albumin groups) (<i>P</i>=.05), survived 28 days. At 24 hours, the HA-1A group had lower mean arterial pressure (<i>P</i>=.04) and cardiac index (<i>P</i>=.004) and higher lactate levels (<i>P</i>=.05) compared with the combined-controls group. In addition, these parameters in the HA-1A group were significantly more predictive of death. The HA-1 A and combined-controls groups had similar significant increases in the level of endotoxemia and bacteremia. Studies of toxic effects showed no harmful effects of control human IgM antibody in infected animals or HA-1 A in noninfected animals. <h3>Conclusion.</h3> —In a canine model of<i>E coli</i>sepsis, HA-1 A did not alter levels of bacteremia or endotoxemia and actually decreased survival. If these data are relevant to human septic shock, HA-1 A therapy should be limited until the conditions under which this monoclonal antibody has beneficial or deleterious effects are more completely defined. (<i>JAMA</i>. 1993;269:2221-2227)
Mind the Gap
Authors: Kirk R. Smith, Jennifer L. Peel
Journal: Environmental Health Perspectives (2010)

Recent analysis has demonstrated a remarkably consistent, nonlinear relationship between estimated inhaled dose of combustion particles measured as PM(2.5) (particulate matter with aerodynamic diameter ≤ 2.5 µm) and cardiovascular disease mortality over several orders of magnitude of dose--from cigarette smoking, environmental tobacco smoke (ETS) exposure, and ambient air pollution exposure.Here we discuss the implications of this relationship and point out the gaps in our knowledge that it reveals.The nonlinear exposure-response relationship that is revealed-much steeper at lower than at higher doses-explains the seemingly inconsistent risks observed from ambient air pollution and cigarette smoking but also raises important questions about the relative benefits of control at different points along the curve. This analysis also reveals a gap in the evidence base along the dose-response curve between ETS and active smoking, which is the dose range experienced by half the world's population from indoor biomass and coal burning for cooking and heating.The shape of the exposure-response relationship implies much larger public health benefits of reductions at the lower end of the dose spectrum (e.g., from reductions in outdoor air pollution) than from reducing the rate of active smoking, which seems counterintuitive and deserving of further study because of its importance for control policies. In addition, given the potential risks and consequent global disease burden, epidemiologic studies are urgently needed to quantify the cardiovascular risks of particulate matter exposures from indoor biomass burning in developing countries, which lie in the dose gap of current evidence.
Simpler vaccine schedules target more tykes
Authors: C. Marwick
Journal: JAMA (1993)

IN AN effort to get most, if not all, of the 2-year-old children in the United States immunized with all the currently recommended vaccines, childhood immunization schedules are being simplified. At a regular meeting of the Advisory Committee on Immunization Practices (ACIP), "we had several discussions about the current childhood immunization schedule, with a view to making it easier to increase coverage in preschool children," says Stephen C. Hadler, MD, chief of the Surveillance, Investigation, and Research Branch of the National Immunization Program at the Centers for Disease Control and Prevention, Atlanta, Ga. The Clinton administration has called for the immunization of 90% of the nation's children under 2 years of age by 1996 with [all] the currently recommended childhood vaccines. This means three doses of diphtheria-tetanus-pertussis (DTP) vaccine, three doses of oral polio vaccine; three doses of<i>Haemophilus influenzae</i>type b conjugate vaccine, and one dose of measles-mumps-rubella vaccine
Wound Healing
Authors: Rudolph J. Noer
Journal: JAMA (1968)

A distinguished group of scholars gathered in Glasgow to pay homage to Lister on the 100th anniversary of his introduction of the<i>Antiseptic Treatment of Wounds</i>. Most appropriately, the centenary took the form of a series of programs relating to the healing of wounds by a group of authorities in that field. This book presents that symposium in printed form. There are four sections: "The Local Response to Injury," "Wound Infection," "The Constitutional Response to Injury," and "Wound Healing." Twenty-three chapters cover a variety of subjects, among them acute and chronic inflammation, tissue repair, the control of infections, nutritional and metabolic responses to injury, differential organ blood flow, effects of hyperbaric oxygen and hypothermia, and alterations in acid-base status. The final section considers more specifically the basic processes directly involved in repair. This work is devoted to basic investigation. There is little so-called practical information immediately applicable to patient care.
A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism
Authors: Ariel Pribluda, Ela Elyada, Zoltan Wiener, Haya Hamza, Robert E. Goldstein, Moshe Biton, Ido Burstain, Yael Morgenstern, Guy Brachya, Hana Billauer, Sharon Biton, Irit Snir-Alkalay, Domagoj Vucic, Katharina Schlereth, Marco Mernberger, Thorsten Stiewe, Moshe Oren, Kari Alitalo, Eli Pikarsky, Yinon Ben-Neriah
Journal: Cancer Cell (2015)
胃造口用于大疱性表皮松解
Authors: A.P.C. Zidorio, E.S. Dutra, L.C.G. Castro, K.M.B. Carvalho
Journal: British Journal of Dermatology (2018)

大疱性表皮松解(EB)是持续终生的遗传水疱型疾病,可能会影响身体内表面和皮肤。患有严重EB的人群会因多种原因出现饮食困难,包括口疮、龋齿、吞咽困难和食欲不振。同时,他们需要多于正常人的蛋白质和卡路里,以修复经常起水疱、流血和破损的皮肤。在其他情况下,饮食问题可利用通过鼻孔进入胃部的“鼻”饲管规避,但是这种饲管需要用胶带固定,可能损害EB皮肤。替代方法是通过小型手术将“胃造口”管通过腹部皮肤直接插入胃部,并通过内部球囊固定,因此无需胶带。本论文在巴西发表,评述了大量医学文献,以弄清胃造口管是否让EB患者实际受益。由于EB的罕见性,先前并没有随机对照试验,并且在641份相关论文中,只有7份提供了关于患者和此问题解决结果的充分详情。他们总结道,营养状况通常会(但并非总是)改善疾病,而且即使疾病恶化,患者的生活质量也会有所改善,其原因可能是饮食压力得到减轻。并发症会导致10%的患者拆除胃造口管。随附的评论指出,要解答就胃造口相关技术、时机和饮食以及结果方面提出的许多其他问题,还需要更多数据。